3) Review the # of patients required to assess efficacy & safety in the <18yo population
4) Review "# needed to treat" (NNT) & "# needed to harm" (NNH)
5) Extend discussion to "# needed to vaccinate" (NNV) & possible limitations of this concept
2/n
I downloaded the VAERS data for 6-17yo (so effectively just 16yo and 17yo) validated through 5/19/2021. I restricted analysis only "serious" events (returned 124 results).
As some have noted, some VAERS entries, even ones labeled "serious", are a bit silly.
They are known side effects or clearly incidental (i.e., emotional reactions to the circumstances, mistakes on age).
Not counted by me: vague reports, moderate allergic or other reactions
4/n
But there is already some signal in just this cohort:
9 Critical condition
3 Cardiac Arrests
1 Stroke while on anticoagulation
1 Guillan Barre Syndrome
6 anaphylaxis (1 counted in the PICU tally)
6 new onset or exacerbation of seizures
4 Myocarditis/Pericarditis
5/n
Fully Vaccinated by 4/20/21: 3.10% (260400)
Fully Vaccinated by 5/20/21: 19.90% (1671600) covid.cdc.gov/covid-data-tra…
Serious Adverse Events (AE) as of 5/19/21: 29
Reporting Lag: assumed @ ~1 month. A serious pediatric event I reported in mid-April was not in my download.
6/n
Download from VAERS Wonder was on 5/19/21 so it's likely that the 4/20/21 serious AE rate above is more accurate.
7/n
C19 mortality for kids is very low, but the exact number is difficult to pin down.
Estimation method based upon CDC numbers with references providing low and high bounds.
8/n
Consequently, roughly speaking, in the best case scenario, the AE rate essentially matches COVID-19 mortality in the <18yo group.
When probabilities of harm from COVID-19 are so low, treatment trials should have sufficient power to detect rare adverse events.
9/n
Since almost all treatment has the potential for adverse events, when examining treatments, we often look at the NNT (number needed to treat) and NNH (number needed to harm): cebm.ox.ac.uk/resources/ebm-…
Traditionally, when NNT > NNH, a treatment is justifiable (excluding cost)
10/n
But to accurately assess NNH, we need to know the underlying rate of adverse events with a treatment.
In order to do so, the initial treatment trial must have "adequate power": they must have a sufficient number of patients in the trial to detect rare AEs.
11/n
If we want 95% certainty that we've detect at least *ONE* AE, required sample depends on the event rate.
From Tweet 7:
With AE with rate 0.00011 => need 30,000 patients
With AE rate of 0.000017 => need 180,000 patients
Fortunately, myocarditis tends to have a benign course in most. In my download, the 4 reported cases appeared to do well.
14/n
But I am deeply concerned about how we went about the decision making for low risk Pediatric populations when the NNH > NNT.
Even more than adults, there are clear risk factors that put a child at greater risk of severe COVID-19. Why not tailor guidance to at risk groups?
15/n
While there are always one-off exceptions, we know obesity plays a larger role for severe disease in younger populations (kids and younger adults):
Some will argue that the NNT (NNV in this case) "goes to zero" because unvaccinated children can transmit to susceptible adults increasing the benefit to vaccinating children by breaking that chain of transmission: both primary infection and reinfection.
17/n
There are several problems with this hypothesis:
1) One has to establish that children drive the epidemic
2) Reinfection and infection post-vaccination results in severe COVID-19
18/n
We can now construct a simple quantitative thought exercise if NNT is significantly altered by Pediatric transmission concerns.
20/n
For the exercise, let's create an incredibly basic transmission model where either kids (K) or adults (A) are transmitting. Furthermore, we assume that K->A is the same as A->K. Both assumptions bias towards vaccinating the young to decrease transmission to at risk adults.
21/n
Referring to the attached, using a binomial expansion for the approximation and using the standard errors provided in the NBER paper, you can see that within 2 years, kids drive <1% of all transmission. Within 3 years, it's under 0.1%.
Kids do/will not drive this pandemic.
22/n
As for the dangers of infection after vaccination or primary infection, we have abundant data that is reassuring in this regard.
Rising vaccination will amplify natural processes in play (see images)
23/n
But we keep seeing "experts" like @DrLeanaWen pushing an innumerate narrative. Maybe she spends too much time with media to examine the data or have someone help her understand it. She has been repeatedly wrong and can't correct her ways.
The quoted thread, applies to all aspects of COVID policy.
One can’t discuss the limitations of archaic compartmental models, subtleties of inferential statistics, & computational modeling under uncertainty to incurious, social-credit seeking politicized acolytes.